Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment InformationMOON SHOTS PROGRAM
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) exist along a continuous disease spectrum starting with early-stage MDS, which may progress to advanced MDS, AML, cured AML or resistant AML. The disease is characterized by an overproduction of immature blood cells. The resulting lack of mature, healthy blood cells causes anemia and an increased risk for infection and bleeding. Around 5-10% of patients with solid tumors who are treated with chemotherapy, radiation or autologous stem cell transplantation develop treatment-related MDS or AML. The majority of patients with MDS and AML are not cured with available therapies, underscoring the urgent need for new therapeutic alternatives that will improve the clinical outcomes of these patients.
The MDS and AML Moon Shot® is revolutionizing the conventional medical research approach to rapidly adapt pre-clinical findings into MDS and AML treatment options.
Your gift can help propel new clinical trials aimed at improving
outcomes for MDS and AML patients who face drug resistance and disease
relapse.
A Phase II trial led by researchers at MD Anderson found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma.
Learn moreA study at MD Anderson identified a new therapeutic target in cancer cells and explains how new anti-cancer drugs called imipridones work by inducing cancer cell death in blood cancers, such as acute myeloid leukemia (AML) and mantle cell lymphoma.
MDS/AML is an aggressive disease with few treatment options. Simona Colla, Ph.D., is leading research efforts of the Moon Shot to better understand and overcome the resistance of MDS to current treatments.
